An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Surmodics, Inc. (NASDAQ: SRDX) announced a presentation at the Gilmartin Emerging Growth Company Showcase on August 31, 2022 at 12:30 p.m. ET. The presentation will feature CEO Gary Maharaj and CFO Tim Arens. Interested investors can access a live audio webcast via this link or through the investor relations section of the company’s website. The archived presentation will be available for 90 days post-event. Surmodics specializes in medical devices and in vitro diagnostic technologies.
Positive
None.
Negative
None.
Webcast is Live at 12:30 p.m. ET
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation to the investment community at the Gilmartin Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 12:30 p.m. ET. A live audio webcast of the presentation will be available at the following link: https://kvgo.com/corporate-services/surmodics-aug-2022. Additionally, access the live audio webcast by navigating to the upcoming events under the investor relations portion of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations and clicking on the webcast icon. The webcast will be archived on the Company’s website for 90 days following the live presentation.
About Surmodics, Inc.
Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission (“SEC”).